KR101128577B1 - Ｘ선 조영제로서의 텅스텐 입자 - Google Patents

Ｘ선 조영제로서의 텅스텐 입자 Download PDF

Info

Publication number
KR101128577B1
KR101128577B1 KR1020067010346A KR20067010346A KR101128577B1 KR 101128577 B1 KR101128577 B1 KR 101128577B1 KR 1020067010346 A KR1020067010346 A KR 1020067010346A KR 20067010346 A KR20067010346 A KR 20067010346A KR 101128577 B1 KR101128577 B1 KR 101128577B1
Authority
KR
South Korea
Prior art keywords
delete delete
particle
tungsten
particles
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020067010346A
Other languages
English (en)
Korean (ko)
Other versions
KR20060118515A (ko
Inventor
오스카르 악셀손
이브 레운바크
마그누스 카를손
Original Assignee
지이 헬스케어 에이에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NO20035294A external-priority patent/NO20035294D0/no
Application filed by 지이 헬스케어 에이에스 filed Critical 지이 헬스케어 에이에스
Publication of KR20060118515A publication Critical patent/KR20060118515A/ko
Application granted granted Critical
Publication of KR101128577B1 publication Critical patent/KR101128577B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A61K49/0428—Surface-modified nanoparticles, e.g. immuno-nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0419—Microparticles, microbeads, microcapsules, microspheres, i.e. having a size or diameter higher or equal to 1 micrometer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B22F1/05—Metallic powder characterised by the size or surface area of the particles
    • B22F1/054—Nanosized particles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B22F1/10—Metallic powder containing lubricating or binding agents; Metallic powder containing organic material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F9/00—Making metallic powder or suspensions thereof
    • B22F9/16—Making metallic powder or suspensions thereof using chemical processes
    • B22F9/18—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds
    • B22F9/24—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds starting from liquid metal compounds, e.g. solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Composite Materials (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Materials Engineering (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
KR1020067010346A 2003-11-28 2004-11-26 Ｘ선 조영제로서의 텅스텐 입자 Expired - Fee Related KR101128577B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
NO20035294A NO20035294D0 (no) 2003-11-28 2003-11-28 Forbindelser
NO20035294 2003-11-28
NO20044622 2004-10-26
NO20044622 2004-10-26
PCT/NO2004/000364 WO2005051435A2 (en) 2003-11-28 2004-11-26 Tungsten particles as x-ray contrast agents

Publications (2)

Publication Number Publication Date
KR20060118515A KR20060118515A (ko) 2006-11-23
KR101128577B1 true KR101128577B1 (ko) 2012-03-28

Family

ID=34635761

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067010346A Expired - Fee Related KR101128577B1 (ko) 2003-11-28 2004-11-26 Ｘ선 조영제로서의 텅스텐 입자

Country Status (10)

Country Link
US (1) US20070031339A1 (https=)
EP (1) EP1694366A2 (https=)
JP (1) JP4974222B2 (https=)
KR (1) KR101128577B1 (https=)
AU (1) AU2004292917A1 (https=)
BR (1) BRPI0416993A (https=)
CA (1) CA2547476A1 (https=)
MX (1) MXPA06006044A (https=)
RU (1) RU2361617C2 (https=)
WO (1) WO2005051435A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO20052429D0 (no) * 2005-05-20 2005-05-20 Amersham Health As Konstrastmidler
NO20052428D0 (no) * 2005-05-20 2005-05-20 Amersham Health As Kontrastmidler
US8173166B2 (en) * 2005-09-09 2012-05-08 Honda Motor Co., Ltd. Methods of producing tungsten nanoparticles
US9149545B2 (en) 2005-11-02 2015-10-06 General Electric Company Nanoparticle-based imaging agents for X-ray/computed tomography and methods for making same
US20070122620A1 (en) * 2005-11-02 2007-05-31 General Electric Company Nanoparticle-based imaging agents for x-ray / computed tomography and methods for making same
US8003883B2 (en) 2007-01-11 2011-08-23 General Electric Company Nanowall solar cells and optoelectronic devices
US7977568B2 (en) 2007-01-11 2011-07-12 General Electric Company Multilayered film-nanowire composite, bifacial, and tandem solar cells
CN100565156C (zh) * 2007-02-09 2009-12-02 中国钢铁股份有限公司 混凝土结构物的裂缝检测方法
RU2508053C2 (ru) 2008-07-07 2014-02-27 Конинклейке Филипс Электроникс Н.В. Визуализация к-края
EP2376137A2 (en) * 2008-11-23 2011-10-19 Medtronic, Inc. Medical devices with encapsulated visibility particles
WO2013022499A2 (en) * 2011-04-22 2013-02-14 Emory University Polymer coated metal particles and uses related thereto
WO2013034446A1 (en) * 2011-09-07 2013-03-14 Dahan Elodie An apparatus and method for generating useful energy
US9989482B2 (en) * 2016-02-16 2018-06-05 General Electric Company Methods for radiographic and CT inspection of additively manufactured workpieces
US20200179539A1 (en) * 2016-06-22 2020-06-11 Board Of Regents, The University Of Texas System Contrast Agents and Methods of Making the Same for Spectral CT That Exhibit Cloaking and Auto-Segmentation
JP2019128288A (ja) * 2018-01-25 2019-08-01 三井化学株式会社 きずの観察方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096474A1 (en) 2001-05-30 2002-12-05 Tecres S.P.A. Bone cement containing coated radiopaque particles and its preparation
WO2003075961A2 (en) * 2002-03-08 2003-09-18 James Hainfeld Gold nanoparticles used for x-rays imaging

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181626A (en) * 1977-12-27 1980-01-01 Ppg Industries, Inc. Method of preparing tungsten hexacarbonyl containing polymers and polymers prepared thereby
US5314679A (en) * 1986-07-03 1994-05-24 Advanced Magnetics Inc. Vascular magnetic resonance imaging agent comprising nanoparticles
DE69207589T2 (de) * 1992-06-01 1996-05-23 Basf Ag Anwendung von Dispersionen von magneto-ionischen Partikeln in MRI-Kontrast-Mitteln
US5728590A (en) * 1994-07-29 1998-03-17 Nanoprobes, Inc. Small organometallic probes
AU687093B2 (en) * 1994-09-27 1998-02-19 Nycomed Imaging As Contrast agent
US5759230A (en) * 1995-11-30 1998-06-02 The United States Of America As Represented By The Secretary Of The Navy Nanostructured metallic powders and films via an alcoholic solvent process
JP3411497B2 (ja) * 1998-03-25 2003-06-03 科学技術振興事業団 Ｗ超微粒子とその製造方法、およびｗナノ結晶薄膜
FR2777016B1 (fr) * 1998-04-06 2002-06-14 Rhone Poulenc Agrochimie Silicone azotee utile pour compacter les sequences d'acides nucleiques et utilisation pour la transfection
WO2000028920A1 (en) * 1998-11-13 2000-05-25 Biocompatibles Limited Therapeutic use of polymers
US6203778B1 (en) * 1998-12-08 2001-03-20 The Regents Of The University Of California Particulate radiopaque contrast agent for diagnostic imaging and microvascular characterization
RU2173173C2 (ru) * 1999-05-12 2001-09-10 Институт химии твердого тела Уральского Отделения РАН Средство для контрастирования при рентгенодиагностике (варианты) и способ его получения
RU2172990C2 (ru) * 1999-06-01 2001-08-27 Валерий Иванович Печенкин Рентгенопоглощающий материал
CA2401270A1 (en) * 2000-03-10 2001-09-20 Jeff W. Lichtman Method for labeling individual cells
CA2309575A1 (en) * 2000-05-26 2001-11-26 James E. Guillet Internally cross-linked macromolecules
JP2004537551A (ja) 2001-07-20 2004-12-16 イオメド インコーポレイテッド メトトレキサートに基づく薬剤を投与することによって腫瘍性、血管原性、繊維芽細胞性及び／又は免疫抑制性眼球異常を治療する方法及びメトトレキサートに基づく薬剤を送達するための眼球イオン導入装置。
FR2830022B1 (fr) * 2001-09-26 2004-08-27 Cime Bocuze Alliage base tungstene fritte a haute puissance
US6686308B2 (en) * 2001-12-03 2004-02-03 3M Innovative Properties Company Supported nanoparticle catalyst
US7462366B2 (en) * 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
US8012454B2 (en) * 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002096474A1 (en) 2001-05-30 2002-12-05 Tecres S.P.A. Bone cement containing coated radiopaque particles and its preparation
WO2003075961A2 (en) * 2002-03-08 2003-09-18 James Hainfeld Gold nanoparticles used for x-rays imaging

Also Published As

Publication number Publication date
MXPA06006044A (es) 2006-09-04
RU2006117818A (ru) 2008-01-10
RU2361617C2 (ru) 2009-07-20
EP1694366A2 (en) 2006-08-30
AU2004292917A1 (en) 2005-06-09
JP2007512322A (ja) 2007-05-17
WO2005051435A2 (en) 2005-06-09
BRPI0416993A (pt) 2007-02-06
WO2005051435A3 (en) 2006-07-13
CA2547476A1 (en) 2005-06-09
JP4974222B2 (ja) 2012-07-11
US20070031339A1 (en) 2007-02-08
KR20060118515A (ko) 2006-11-23

Similar Documents

Publication Publication Date Title
Marasini et al. Integration of gadolinium in nanostructure for contrast enhanced‐magnetic resonance imaging
KR101128577B1 (ko) Ｘ선 조영제로서의 텅스텐 입자
CN101827614B (zh) 基于镧系元素的纳米颗粒作为放射增敏剂的应用
Sung et al. Multimetallic complexes and functionalized gold nanoparticles based on a combination of d-and f-elements
WO1999012577A1 (en) Polymer particles made of polyvinyl alcohol and comprising a contrast agent for chemoembolization
CN102639153B (zh) 用亲水α‑羟基膦酸共轭物处理水不溶性纳米微粒，这样改性的纳米微粒及其作为造影剂的用途
KR20130015509A (ko) 단당류 인산 또는 그 유도체로 표면이 개질된 친수성 나노입자, 그의 콜로이드 용액 및 그 용도
JP4758346B2 (ja) 高分子ミセル型ｍｒｉ造影剤
JP5674941B2 (ja) ヨードを含有した放射形状の高分子化合物、その製造方法及びそれを含有するｃｔ用造影剤組成物
JP5651468B2 (ja) Ｍｒｉ造影能を有する重合体−金属錯体複合体、並びにそれを用いたｍｒｉ造影用及び／又は抗腫瘍用組成物
Stanicki et al. Impact of the chain length on the biodistribution profiles of PEGylated iron oxide nanoparticles: A multimodal imaging study
Simao et al. Laser-synthesized ligand-free Au nanoparticles for contrast agent applications in computed tomography and magnetic resonance imaging
US20180236106A1 (en) Radiographic nanoparticle contrast agents for dual-energy x-ray imaging and computed tomography scanning and methods of using thereof
EP3119203A1 (en) Polyphosphazene delivery system for metal nanocrystals
EP1883428B1 (en) Contrast agents
US20100278749A1 (en) Nanoparticle contrast agents for diagnostic imaging
WO2010029947A1 (ja) 造影剤組成物及びその製造方法
CN101193659A (zh) 作为x－射线造影剂的钨粒子
US20080233052A1 (en) Contrast Agents
US20100278734A1 (en) Nanoparticle contrast agents for diagnostic imaging
CN107802844A (zh) 一种负载双造影元素的杂化海藻酸钠纳米凝胶的制备方法
US20120277409A1 (en) Metal-polysaccharide conjugates: compositions, synthesis and methods for cancer therapy
WO2025221635A1 (en) In vivo crosslinkable hydrogels with gold nanoparticles for medical applications

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20150314

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20150314

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000